Androgen Receptor Antagonists for Prostate Cancer Therapy|
With recent evidence that castrate resistant prostate cancer is far from androgen receptor (AR)-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach. [Endocr Relat Cancer]
Novel Bone-Targeting Agents in Prostate Cancer
The authors provide an overview of the multiple emerging novel bone-targeted therapies in prostate cancer. [Prostate Cancer Prostatic Dis]
Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Have we missed an important article or publication in Prostate Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.